Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

202392 citationsJournal Articlehybrid Open Access

Authors

Michael Wang · The University of Texas MD Anderson Cancer Center

Wojciech Jurczak · The Maria Sklodowska-Curie National Research Institute of Oncology

Pier Luigi Zinzani · Istituto di Ematologia di Bologna

Toby A. Eyre · Churchill Hospital

Chan Y. Cheah · The University of Western Australia

Chaitra S. Ujjani · University of Washington

Youngil Koh

Abstract

Pirtobrutinib is a first-in-class novel noncovalent (reversible) BTKi and the first BTKi of any kind to demonstrate durable efficacy after prior cBTKi therapy in heavily pretreated R/R MCL. Pirtobrutinib was well tolerated with low rates of treatment discontinuation because of toxicity.

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment CNS Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Journal of Clinical Oncology

Volume 41, Issue 24, pp. 3988-3997

DOI: 10.1200/jco.23.00562

Field-Weighted Citation Impact: 26.30